Angiochem to Present at Stifel Nicolaus Healthcare Conference 2010

MONTRÉAL--(BUSINESS WIRE)-- Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced that Jean-Paul Castaigne, MD, President and CEO of Angiochem is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 16th at 4:25p.m. EDT.

About Angiochem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing LRP-1, a naturally-occurring receptor on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is about to initiate two separate pivotal clinical programs in patients with brain cancers and brain metastases from lung and breast cancers. Additionally, Angiochem is developing a broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic disorders, brain cancer, pain, and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit

Copyright 2010 Angiochem, Inc.


The Yates Network
Gina Nugent, 617-460-3579

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health


Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.